文献速递白血病淋巴瘤

成人急性淋巴细胞白血病基因组驱动因素与贝林妥欧单抗疗效:ECOG-ACRIN E1910研究

Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
PubMed 文献 · Blood · 2026-10-05

该研究分析ECOG-ACRIN E1910研究中569例BCR::ABL1阴性B-ALL成人患者的基因组与临床数据,鉴定出23种分子亚型及267个候选驱动基因。诱导和强化化疗后MRD阴转率在PAX5alt、TCF3::PBX1和ZNF384-R亚型中较高,在BCR::ABL1-like和KMT2A-R亚型中较低;在多个亚型中,化疗联合贝林妥欧单抗与无复发生存和总生存改善相关,但部分亚型样本量小需验证。

要点

  • 鉴定出23种分子亚型,高危亚型包括BCR::ABL1(20%)、BCR::ABL1-like(18%)、低超二倍体(14%)和KMT2A-R(12%)。
  • MRD阴转率在PAX5alt、TCF3::PBX1和ZNF384-R中较高,在BCR::ABL1-like和KMT2A-R中较低。
  • 贝林妥欧单抗联合化疗在多个B-ALL亚型中与无复发生存和总生存改善相关,但部分亚型样本量小需验证。

核心结论

  • 研究定义了成人B-ALL的基因组改变图谱,并识别出可能影响贝林妥欧单抗联合化疗疗效的基因组亚型。

研究设计与样本

  • 分析ECOG-ACRIN E1910研究(NCT02003222)中569例BCR::ABL1阴性B-ALL成人患者的基因组和临床数据。

主要发现

  • 鉴定出23种分子亚型,包括BCR::ABL1(20%)、BCR::ABL1-like(18%)、低超二倍体(14%)和KMT2A-R(12%),以及267个候选驱动基因。
  • 发现以CEBPA过表达或CEBPB表达升高为特征的亚型,由染色体易位介导的增强子劫持或CEBPA下游插入产生新增强子所致。
  • 诱导和强化化疗后MRD阴转在PAX5alt、TCF3::PBX1和ZNF384-R B-ALL中更常见,在BCR::ABL1-like和KMT2A-R B-ALL中较少见。
  • 基因组与临床数据整合提示,在超二倍体、PAX5alt、PAX5 P80R、BCR::ABL1-like JAK-STAT和KMT2A-R B-ALL等亚型中,化疗联合贝林妥欧单抗与无复发生存和总生存改善相关,但部分亚型样本量小需确认。
  • TP53改变和髓系CHIP相关突变分别见于15.3%和9.8%的患者,与诊断时年龄较大和化疗预后较差相关。

临床怎么用

  • 对于BCR::ABL1阴性B-ALL成人患者,可考虑基因组分型以评估MRD阴转概率及贝林妥欧单抗联合化疗的潜在获益。
  • TP53改变或髓系CHIP相关突变提示化疗预后较差,需关注高危患者治疗策略。

局限性

  • 部分亚型样本量小,贝林妥欧单抗联合化疗的生存获益需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The bispecific CD19/CD3 T-cell engaging antibody blinatumomab is efficacious in front-line therapy in B-cell acute lymphoblastic leukemia (B-ALL) but the biological determinants of response and resistance are incompletely understood. To examine the genomic determinants of outcome, we analyzed genomic and clinical data of 569 adults registered to the ECOG-ACRIN E1910 study of blinatumomab in BCR::ABL1-negative B-ALL (ClinicalTrials.gov NCT02003222). We identified 23 molecular subtypes including the high-risk subtypes BCR::ABL1 (20%), BCR::ABL1-like (18%), low hypodiploid (14%) and KMT2A-R (12%), and 267 putative driver genes. We identified a subtype characterized by CEBPA overexpression or elevated CEBPB expression due to chromosomal translocation-mediated enhancer hijacking, or insertions downstream of CEBPA that generate neoenhancers. Attainment of MRD-negativity patients after induction and intensification chemotherapy was more common in PAX5alt, TCF3::PBX1 and ZNF384-R B-ALL, and less common in BCR::ABL1-like and KMT2A-R B-ALL. Integration of genomic and clinical data suggested that the addition of blinatumomab to chemotherapy was associated with improved relapse-free and overall survival for several B-ALL subtypes, including hyperdiploid, PAX5alt, PAX5 P80R, BCR::ABL1-like JAK-STAT and KMT2A-R B-ALL, although small sample sizes for several subtypes indicate that confirmation is required. Alteration of TP53 or mutations associated with myeloid clonal hematopoiesis of indeterminate potential (CHIP) were identified in 15.3% and 9.8% of patients, respectively. The presence of these mutations was associated with older age at diagnosis and inferior outcome to chemotherapy. In summary, we define the landscape of genomic alterations of adult B-ALL, and identify genomic subtypes that may influence the efficacy of blinatumomab when combined with chemotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhong X, Roberts KG, Wei H, et al. Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. Blood. 2026. PMID: 42832396. doi:10.1182/blood.2026033793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。